Navigating Late Line R/R Multiple Myeloma: Treatment Landscape, Patient Care, and Quality of Life - Episode 5
Clinical Factors Evaluated When Choosing Treatment in Late-Line RRMM
Panelists discuss how treatment selection for late-line relapsed/refractory multiple myeloma (RRMM) balances multiple factors including patient fitness, prior therapy exposure, disease aggressiveness, side effect profiles, logistical considerations (with CAR-T requiring hospitalization while bispecifics can often be administered outpatient), financial accessibility and unique toxicity considerations (such as GPRC5D-targeting therapies affecting the skin and nails versus B-cell maturation antigen [BCMA]–targeting approaches), ultimately requiring a personalized approach weighing effectiveness against practical constraints on a patient-by-patient basis.
Video content above is prompted by the following:
- How do you decide between different treatment approaches, such as bispecific antibodies (BCMA/GPRC5D), CAR T-cell therapy or other targeted treatments?
- What are the differences in effectiveness, side effects and accessibility between these therapies?
Related Content:
